Tempus AI TEM expects full-year 2025 revenues of $1.25 billion (up from the previous $1.24 billion guidance), which represents approximately 80% annual growth. The company also expects adjusted EBITDA ...

Tempus AI Inc. (NASDAQ:TEM) is one of the best young stocks to buy and hold for 5 years. On July 8, Tempus AI announced the ...

Key Takeaways Tempus AI stock shows 15–32% upside potential based on analyst forecasts.The company leads in using artificial ...

Tempus AITEM reached an important technical milestone, with its Relative Strength (RS) Rating moving into the 90-plus ...

ARKK surged in 2Q25 on AI and crypto bets like Circle and Tempus, with strong returns despite outflows and high sector risk.

One of Wood's favorite AI stocks has been criticized by CNBC host Jim Cramer multiple times in 2025, including this week.

Apple's $60 billion cash pile and a rare executive shake-up reignite speculation: will the tech giant finally go on an AI ...

The global AI infrastructure market is projected to grow at a CAGR of 29.1%, reaching $356.14 billion by 2032 from $36.59 billion in 2023, according to Fortune Business Insights.

ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 12, 2025 to file lead plaintiff applications in a ...

Personalis and Tempus AI are adding colorectal cancer as a new indication to their existing commercialization agreement.

GeneDx leverages a vast rare disease database and advanced genomic testing, offering superior insights. Read why I am bullish about WGS stock.

Personalis is extending its agreement with Tempus through November 2029. The two companies are developing a minimal residual disease test to detect breast and lung cancer and solid-tumor immunotherapy ...